AIM ImmunoTech (AIM) AI Stock Analysis

• Market Cap: $6.99M
• Dividend Yield: N/A
• Average Volume (3M): 319.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: -39.80%
• EPS Growth: 56.07%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -3.68
• Shares Outstanding: 2,708,688
• 10 Day Avg. Volume: 62,054
• 30 Day Avg. Volume: 319,450
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: 70.56
• Enterprise Value/Gross Profit: 59.29
• Enterprise Value/Ebitda: -0.56
• 1Y Price Target: $2.50
• Price Target Upside: 0.00%
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 39 Underperform
• Price Target: $2.50 ▲(0.00% Upside)

AIM ImmunoTech's overall stock score is primarily impacted by its poor financial performance and bearish technical indicators. The company's negative profitability, weak balance sheet, and noncompliance with NYSE requirements are significant risks. While recent positive study results and a public offering are potential positives, they do not outweigh the financial and technical challenges.

Positive Factors

Analyst Rating

The analyst maintains a BUY rating for AIM, seeing large upside opportunities that balance high risks with high growth prospects.

Clinical Trials

Positive data from a Phase 2 study for Ampligen as a therapeutic for patients with post-COVID conditions could boost stock performance.

Negative Factors

Corporate Governance

Dissident stockholders have nominated their own slate of directors for the third consecutive year, indicating potential ongoing governance challenges.

Stock Listing

The company's stock has been delisted from NYSE American and is now trading on Pink Open Market, which might impact investor confidence.

AIM ImmunoTech Business Overview & Revenue Model

Company Description

AIM ImmunoTech Inc. is a biotechnology company focused on developing innovative therapies for the treatment of various immune-related diseases and conditions. The company operates primarily in the biopharmaceutical sector, specializing in drug development for cancer and viral diseases. AIM's core product, Ampligen (rintatolimod), is an experimental therapeutic intended for use in various indications, including chronic fatigue syndrome and certain cancers, aiming to enhance the immune response.

How the Company Makes Money

AIM ImmunoTech generates revenue primarily through the development and commercialization of its therapeutic products. The company seeks funding through grants, partnerships, and collaborations with other pharmaceutical firms and research institutions that are interested in its innovative drug candidates. Revenue streams may include milestone payments from partnerships, royalties from product sales, and potentially government funding for research and development projects. Additionally, AIM may explore licensing agreements for its proprietary technologies, which can further contribute to its earnings. The company's financial performance is also influenced by the progress and outcomes of its clinical trials and regulatory approvals, as successful advancements can lead to increased investment and sales opportunities.

AIM ImmunoTech Financial Statement Overview

Summary

AIM ImmunoTech is facing significant financial hurdles characterized by declining revenue, persistent losses, and negative cash flow. While the company has managed its debt levels well, the lack of equity and negative cash flow raise concerns about its long-term financial sustainability.

Income Statement

AIM ImmunoTech has demonstrated declining revenue with negative net income over the past years. Despite a slight improvement in gross profit, EBIT and EBITDA margins remain negative, indicating ongoing operational challenges and a lack of profitability.

Balance Sheet

The company has a strong cash position relative to its total assets, but it faces challenges with zero stockholders' equity, indicating potential financial distress. The absence of debt provides some stability, yet the lack of equity suggests limited growth capacity.

Cash Flow

Operating cash flow remains negative, reflecting persistent cash burn. While the company has managed to secure financing, free cash flow remains negative, and growth in free cash flow is absent, indicating ongoing liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	121.00K	170.00K	202.00K	141.00K	135.00K	163.00K
Gross Profit	144.00K	139.00K	160.00K	-19.78M	-715.00K	-643.00K
EBITDA	-15.26M	-16.49M	-31.68M	-19.87M	-18.25M	-13.02M
Net Income	-16.17M	-17.32M	-28.96M	-21.09M	-21.51M	-16.26M
Balance Sheet
Total Assets	4.13M	8.61M	19.38M	40.49M	57.70M	64.58M
Cash, Cash Equivalents and Short-Term Investments	835.00K	3.98M	13.07M	34.19M	48.27M	39.00M
Total Debt	2.81M	2.94M	718.00K	837.00K	149.00K	2.29M
Total Liabilities	10.68M	9.93M	9.15M	2.02M	820.00K	3.29M
Stockholders Equity	-6.55M	-1.32M	10.23M	38.47M	56.88M	61.29M
Cash Flow
Free Cash Flow	-11.52M	-14.91M	-21.85M	-16.38M	-14.60M	-10.96M
Operating Cash Flow	-10.96M	-14.89M	-21.27M	-16.11M	-13.96M	-10.37M
Investing Cash Flow	5.69M	4.71M	-832.00K	10.99M	-631.00K	-9.16M
Financing Cash Flow	2.19M	6.44M	485.00K	80.00K	8.19M	56.56M

AIM ImmunoTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIM, the sentiment is Negative. The current price of 2.5 is below the 20-day moving average (MA) of 2.66, below the 50-day MA of 6.18, and below the 200-day MA of 12.29, indicating a bearish trend. The MACD of -0.99 indicates Negative momentum. The RSI at 26.87 is Positive, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIM.

AIM ImmunoTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
APLM	42 Neutral	$6.84M	―	-233.67%	―	―	80.54%
AIM	39 Underperform	$6.99M	―	-3138.91%	―	-39.80%	56.07%
GTBP	34 Underperform	$4.06M	―	-181.99%	―	―	46.96%
PMCB	―	$6.87M	0.38	67.08%	―	―	―
PCSA	29 Underperform	$11.26M	―	-212.38%	―	―	57.99%
THAR	―	$28.32M	―	-340.26%	―	―	―

AIM ImmunoTech Corporate Events

AIM ImmunoTech Closes $8 Million Public Offering

On July 31, 2025, AIM ImmunoTech Inc. announced the closing of its public offering, raising approximately $8.0 million through the sale of 2,000,000 shares of common stock and accompanying warrants. The offering, managed by Maxim Group LLC, is expected to bolster the company’s financial position, potentially enhancing its ability to advance its therapeutic developments.

AIM ImmunoTech Reports Positive Phase 2 Study Results

On July 28, 2025, AIM ImmunoTech Inc. announced positive data from its ongoing Phase 2 DURIPANC study, which evaluates the combination of its drug Ampligen® with AstraZeneca’s Imfinzi® for treating metastatic pancreatic cancer. The study, a collaboration with AstraZeneca and Erasmus Medical Center, has shown promising results with no significant toxicity and improved progression-free and overall survival rates. This development suggests a potential benefit in combining Ampligen’s selective innate immune activation with durvalumab’s checkpoint inhibition, offering hope for a new therapy in pancreatic cancer maintenance.

AIM ImmunoTech Faces NYSE Noncompliance Notification

On June 17, 2025, AIM ImmunoTech Inc. received a notification from NYSE American LLC indicating noncompliance with the minimum stockholders’ equity requirements due to a stockholders’ deficit of negative $3.9 million as of March 31, 2025, and consistent losses over the past five fiscal years. Despite a previous warning in December 2024, the company has until June 11, 2026, to regain compliance, and its stock continues to trade on the NYSE American. The notification does not impact the company’s operations or SEC reporting requirements.